Patient and caregiver outcomes after 6 ± 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease: The Belgian FExT study

Tony Mets, Maurits Vandewoude, Jean Jacquy, Anne Deblander, Karen MacDonald, Anne Sloesen, Ivo Abraham

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Fingerprint

Dive into the research topics of 'Patient and caregiver outcomes after 6 ± 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease: The Belgian FExT study'. Together they form a unique fingerprint.

Medicine & Life Sciences